Get the Stockscreener App
14.55
0.07%
0.01
After Hours:
14.55
Adma Biologics Inc stock is traded at $14.55, with a volume of 4.20M.
It is up +0.07% in the last 24 hours and down -9.68% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$14.54
Open:
$14.55
24h Volume:
4.20M
Relative Volume:
1.31
Market Cap:
$3.47B
Revenue:
$474.17M
Net Income/Loss:
$208.93M
P/E Ratio:
17.13
EPS:
0.8493
Net Cash Flow:
$65.61M
1W Performance:
+3.41%
1M Performance:
-9.68%
6M Performance:
-25.00%
1Y Performance:
-15.14%
1-Day Range:
$14.30
$14.62
1-Week Range:
$13.82
$14.82
52-Week Range:
$13.82
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
14.55 | 3.47B | 474.17M | 208.93M | 65.61M | 0.8493 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Sentiment analysis tools applied to ADMA Biologics Inc.Weekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Will ADMA Biologics Inc. rebound enough to break evenJuly 2025 Action & Smart Swing Trading Techniques - newser.com
What momentum shifts mean for ADMA Biologics Inc.Weekly Profit Analysis & AI Optimized Trading Strategy Guides - newser.com
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring a Potential 99.86% Upside in the Biotech Space - DirectorsTalk Interviews
Volume spikes in ADMA Biologics Inc. stock – what they meanWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
Comparing ADMA Biologics Inc. in custom built stock radarsInsider Selling & Precise Buy Zone Tips - newser.com
Is ADMA Biologics Quietly Building Toward $1.1 Bln Revenue Breakout? - RTTNews
Can momentum traders help lift ADMA Biologics Inc.Trade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
Adma Biologics (ADMA) Stock Moves -1.36%: What You Should Know - sharewise.com
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know - sharewise.com
Using data filters to optimize entry into ADMA Biologics Inc.Weekly Profit Recap & High Win Rate Trade Tips - newser.com
What moving averages say about ADMA Biologics Inc.2025 Retail Activity & Safe Entry Point Alerts - newser.com
Is ADMA Biologics Inc. stock oversold or undervaluedMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Using flow based indicators on ADMA Biologics Inc.Trade Volume Report & Weekly High Potential Stock Alerts - newser.com
Weiss Ratings Reaffirms Buy (B-) Rating for ADMA Biologics (NASDAQ:ADMA) - MarketBeat
Can ADMA Biologics Inc. stock beat market expectations this quarter2025 Support & Resistance & Daily Risk Controlled Trade Plans - newser.com
Should you wait for a breakout in ADMA Biologics Inc.Rate Hike & Verified Chart Pattern Signals - newser.com
What MACD and RSI say about ADMA Biologics Inc.2025 Dividend Review & Scalable Portfolio Growth Ideas - newser.com
Is ADMA Biologics Inc. stock trading near support levels2025 Big Picture & Real-Time Stock Entry Alerts - newser.com
Tick level data insight on ADMA Biologics Inc. volatilityJuly 2025 Outlook & Consistent Profit Alerts - newser.com
1,800,440 Shares in ADMA Biologics Inc $ADMA Bought by Vaughan Nelson Investment Management L.P. - MarketBeat
Evaluating ADMA Biologics Inc. with trendline analysisQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
Why Adma Biologics (ADMA) Outpaced the Stock Market Today - sharewise.com
What analysts say about ADMA Biologics Inc stockRisk Mitigation Techniques & Analyze Your Portfolio Risk in Seconds - earlytimes.in
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 5.1%Here's Why - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: A Promising 86.16% Upside in the Biotech Sector - DirectorsTalk Interviews
ADMA Biologics Inc (ADMA) Stock Analysis: Exploring An 86.16% Potential Upside - DirectorsTalk Interviews
Assenagon Asset Management S.A. Sells 387,872 Shares of ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Sold by Ausbil Investment Management Ltd - MarketBeat
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - sharewise.com
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Sep 15 '25 |
Sale |
16.13 |
21,000 |
338,730 |
2,025,850 |
| Grossman Adam S | President and CEO |
Aug 15 '25 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,052,850 |
| Grossman Adam S | President and CEO |
Aug 15 '25 |
Sale |
16.88 |
21,000 |
354,480 |
2,031,850 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance |
Jul 30 '25 |
Option Exercise |
8.98 |
2,500 |
22,450 |
489,898 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,058,850 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Sale |
18.66 |
21,000 |
391,860 |
2,037,850 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):